

BARCLAYS PLC  
Form FWP  
August 04, 2016

**Free Writing Prospectus  
Filed Pursuant to Rule 433  
Reg-Statement No. 333-195645**

**USD 1.35bn 3.20% Fixed Rate Senior Notes due 2021**

**Pricing Term Sheet**

<b>Issuer:</b>	Barclays PLC
<b>Notes:</b>	USD 1.35bn 3.20% Fixed Rate Senior Notes due 2021
<b>Expected Issue Ratings<sup>1</sup>:</b>	Baa3 (Moody's) / BBB (S&P) / A (Fitch)
<b>Status:</b>	Senior Debt / Unsecured
<b>Legal Format:</b>	SEC registered
<b>Principal Amount:</b>	USD 1,350,000,000
<b>Trade Date:</b>	August 3, 2016
<b>Settlement Date:</b>	August 10, 2016 (T+5)
<b>Maturity Date:</b>	August 10, 2021
<b>Coupon:</b>	3.20%
<b>Interest Payment Dates:</b>	Semi-annually in arrear on August 10 and February 10 in each year, commencing on February 10, 2017 and ending on the Maturity Date
<b>Coupon Calculation:</b>	30/360, following, unadjusted
<b>Business Days:</b>	New York, London
<b>U.K. Bail-in Power Acknowledgement:</b>	Yes. See section entitled "Description of Senior Notes Agreement with Respect to the Exercise of U.K. Bail-in Power" in the Preliminary Prospectus Supplement dated August 3, 2016 (the "Preliminary Prospectus Supplement").
<b>Tax Redemption</b>	If there is a Tax Event (as defined in the Preliminary Prospectus Supplement), the Issuer may, at its option, at any time, redeem the notes, in whole but not in part, at a redemption price equal to 100% of their principal amount, together with any accrued but unpaid interest to (but excluding) the date fixed for redemption, as further described and subject to the conditions specified in the Preliminary Prospectus Supplement.
<b>Benchmark Treasury:</b>	T 1.125 07/31/21
<b>Spread to Benchmark:</b>	215 bps
<b>Reoffer Yield:</b>	3.214%

<b>Issue Price:</b>	99.936%
<b>Underwriting Discount:</b>	0.325%
<b>Net Proceeds:</b>	USD 1,344,748,500
<b>Sole Bookrunner:</b>	Barclays Capital Inc.

<sup>1</sup> Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.

<b>Co-managers:</b>	ABN AMRO Securities (USA) LLC; BBVA Securities Inc.; Blaylock Beal Van, LLC; BMO Capital Markets Corp.; CastleOak Securities, L.P.; MFR Securities, Inc.; Mizuho Securities USA Inc.; MUFG Securities Americas Inc.; Multi-Bank Securities, Inc.; PNC Capital Markets LLC; Regions Securities LLC; Scotia Capital (USA) Inc.; SMBC Nikko Securities America, Inc.; Société Générale; TD Securities (USA) LLC; U.S. Bancorp Investments, Inc.; Wells Fargo Securities, LLC
<b>Risk Factors:</b>	An investment in the notes involves risks. See Risk Factors section beginning on page S-9 of the Preliminary Prospectus Supplement.
<b>Denominations:</b>	USD 200,000 and integral multiples of USD 1,000 in excess thereof
<b>ISIN/CUSIP:</b>	US06738EAQ89 / 06738E AQ8
<b>Settlement:</b>	DTC; Book-entry; Transferable
<b>Documentation:</b>	To be documented under the Issuer's shelf registration statement on Form F-3 (No. 333-195645) and to be issued pursuant to the Senior Debt Indenture dated November 10, 2014 between the Issuer and The Bank of New York Mellon acting through its London Branch, as trustee (the Trustee )
<b>Listing:</b>	We will apply to list the notes on the New York Stock Exchange
<b>Governing Law:</b>	New York law
<b>Definitions:</b>	Unless otherwise defined herein, all capitalized terms have the meaning set forth in the Preliminary Prospectus Supplement

**The Issuer has filed a registration statement (including a prospectus dated May 2, 2014 (the Prospectus ) and the Preliminary Prospectus Supplement) with the U.S. Securities and Exchange Commission ( SEC ) for this offering. Before you invest, you should read the Prospectus and the Preliminary Prospectus Supplement for this offering in that registration statement, and other documents the Issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by searching the SEC online database (EDGAR®) at [www.sec.gov](http://www.sec.gov). Alternatively, you may obtain a copy of the Prospectus and the Preliminary Prospectus Supplement from Barclays Capital Inc. by calling 1-888-603-5847.**